nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.03.2022 | Original Article

Comparison of the diagnostic efficacy of ⁶⁸ Ga-FAPI-04 PET/MR and ¹⁸F-FDG PET/CT in patients with pancreatic cancer

verfasst von: Zeyu Zhang, Guorong Jia, Guixia Pan, Kai Cao, Qinqin Yang, Hongyu Meng, Jian Yang, Lu Zhang, Tao Wang, Chao Cheng, Changjing Zuo

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We sought to assess the performance of ⁶⁸ Ga-FAPI-04 PET/MR for the diagnosis of primary tumours as well as metastatic lesions in patients with pancreatic cancer and to compare the results with those of ¹⁸F-FDG PET/CT.

Methods

Prospectively, we evaluated 33 patients suspected to have pancreatic adenocarcinoma, of whom thirty-two were confirmed by histopathology, and one had autoimmune pancreatitis confirmed by needle biopsy and glucocorticoid treatment. Within 1 week, each patient underwent both ⁶⁸ Ga-FAPI-04 PET/MR and ¹⁸F-FDG PET/CT. Comparisons of the detection abilities for primary tumours, lymph nodes, and metastases were conducted for the two imaging approaches. The original maximum standard uptake values (SUV_max) and normalised SUV_max (SUV_max/SUV_bkgd) of paired lesions on ⁶⁸ Ga-FAPI-04 PET/MR and ¹⁸F-FDG PET/CT were measured and compared.

Results

Thirty pancreatic cancer patients and three pancreatitis patients were enrolled. ⁶⁸ Ga-FAPI-04 PET/MR and ¹⁸F-FDG PET/CT exhibited equivalent (100%) detection rates for primary tumours. The original/normalised SUV_max of primary tumours on ⁶⁸ Ga-FAPI-04 PET was markedly higher than that on ¹⁸F-FDG (p < 0.05). Sixteen pancreatic cancer patients had pancreatic parenchymal uptake, whereas ¹⁸F-FDG PET images showed parenchymal uptake in only four patients (53.33% vs. 13.33%, p < 0.001). ⁶⁸ Ga-FAPI-04 PET detected more positive lymph nodes than ¹⁸F-FDG PET (42 vs. 30, p < 0.001), while ¹⁸F-FDG PET was able to detect more liver metastases than ⁶⁸ Ga-FAPI-04 (181 vs. 104, p < 0.001). In addition, multisequence MR imaging helped explain ten pancreatic cancers that could not be definitively revealed due to ⁶⁸ Ga-FAPI-04 inflammatory uptake and identified more liver metastases than ¹⁸F-FDG (256 vs. 181, p < 0.001).

Conclusion

⁶⁸ Ga-FAPI-04 PET might be better than ¹⁸F-FDG PET in the detection of suspicious lymph node metastases. MR multiple sequence imaging of ⁶⁸ Ga-FAPI-04 PET/MR was helpful for explaining pancreatic lesions in patients with obstructive inflammation and detecting tiny liver metastases.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. https://doi.org/10.1038/nrdp.2016.22.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957–63. https://doi.org/10.1097/SLA.0b013e3181b2fafa.CrossRefPubMed

Lee JW, O JH, Choi M, Choi JY. Impact of F-18 fluorodeoxyglucose PET/CT and PET/MRI on initial staging and changes in management of pancreatic ductal adenocarcinoma: a systemic review and meta-analysis. Diagnostics (Basel). 2020;10:952. https://doi.org/10.3390/diagnostics10110952.

Wang L, Dong P, Shen G, Hou S, Zhang Y, Liu X, et al. 18F-Fluorodeoxyglucose positron emission tomography predicts treatment efficacy and clinical outcome for patients with pancreatic carcinoma: a meta-analysis. Pancreas. 2019;48:996–1002. https://doi.org/10.1097/MPA.0000000000001375.CrossRefPubMed

Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CH. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol. 2014;40:794–804. https://doi.org/10.1016/j.ejso.2014.03.016.CrossRefPubMed

Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454–67. https://doi.org/10.1038/nrgastro.2012.115.CrossRefPubMed

Nielsen MFB, Mortensen MB, Detlefsen S. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. World J Gastroenterol. 2018;24:4663–78. https://doi.org/10.3748/wjg.v24.i41.4663.CrossRefPubMedPubMedCentral

Whittle MC, Hingorani SR. Fibroblasts in pancreatic ductal adenocarcinoma: biological mechanisms and therapeutic targets. Gastroenterology. 2019;156:2085–96. https://doi.org/10.1053/j.gastro.2018.12.044.CrossRefPubMed

10.

Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873:188356. https://doi.org/10.1016/j.bbcan.2020.188356.CrossRefPubMedPubMedCentral

11.

von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017;10:76. https://doi.org/10.1186/s13045-017-0448-5.CrossRef

12.

Mikuła-Pietrasik J, Uruski P, Tykarski A, Książek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci. 2018;75:509–25. https://doi.org/10.1007/s00018-017-2663-1.CrossRefPubMed

13.

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, et al. FAP Promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2016;76:4124–35. https://doi.org/10.1158/0008-5472.CAN-15-2973.CrossRefPubMed

14.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRefPubMedPubMedCentral

15.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92. https://doi.org/10.2967/jnumed.118.215913.CrossRefPubMedPubMedCentral

16.

Röhrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86. https://doi.org/10.2967/jnumed.120.253062.CrossRefPubMedPubMedCentral

17.

Sagiyama K, Watanabe Y, Kamei R, Hong S, Kawanami S, Matsumoto Y, et al. Multiparametric voxel-based analyses of standardized uptake values and apparent diffusion coefficients of soft-tissue tumours with a positron emission tomography/magnetic resonance system: preliminary results. Eur Radiol. 2017;27:5024–33. https://doi.org/10.1007/s00330-017-4912-y.CrossRefPubMed

18.

Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2018;43:415–34. https://doi.org/10.1007/s00261-017-1374-2.CrossRef

19.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22. https://doi.org/10.2967/jnumed.118.210443.CrossRefPubMed

20.

Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63(1):81–8. https://doi.org/10.2967/jnumed.120.258467.

21.

González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, et al. Omics approaches in pancreatic adenocarcinoma. Cancers (Basel). 2019;11:1052. https://doi.org/10.3390/cancers11081052.CrossRef

22.

Kleeff J, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T, et al. Chronic pancreatitis. Nat Rev Dis Primers. 2017;3:17060. https://doi.org/10.1038/nrdp.2017.60

23.

Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT. J Nucl Med. 2021;62:266–71. https://doi.org/10.2967/jnumed.120.244723.CrossRefPubMed

24.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32. https://doi.org/10.1007/s00259-020-04769-z.CrossRefPubMed

25.

Qin C, Liu F, Huang J, Ruan W, Liu Q, Gai Y, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021;48:3228–37. https://doi.org/10.1007/s00259-021-05255-w.CrossRefPubMed

26.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9. https://doi.org/10.2967/jnumed.118.224469.CrossRefPubMedPubMedCentral

27.

Kanematsu M, Hoshi H, Yamada T, Nandate Y, Kato M, Yokoyama R, et al. Overestimating the size of hepatic malignancy on helical CT during arterial portography: equilibrium phase CT and pathology. J Comput Assist Tomogr. 1997;21:713–9. https://doi.org/10.1097/00004728-199709000-00006.CrossRefPubMed

28.

Peng J, Wang Y, Zhang R, Deng Y, Xiao B, Ou Q, et al. Immune cell infiltration in the microenvironment of liver oligometastasis from colorectal cancer: intratumoural CD8/CD3 ratio is a valuable prognostic index for patients undergoing liver metastasectomy. Cancers (Basel). 2019;11:1922. https://doi.org/10.3390/cancers11121922.CrossRef

29.

Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014;20:15580–9. https://doi.org/10.3748/wjg.v20.i42.15580.CrossRefPubMedPubMedCentral

30.

Sharon Y, Raz Y, Cohen N, Ben-Shmuel A, Schwartz H, Geiger T, et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res. 2015;75:963–73. https://doi.org/10.1158/0008-5472.CAN-14-1990.CrossRefPubMed

31.

Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019;68:159–71. https://doi.org/10.1136/gutjnl-2018-316451.CrossRefPubMed

32.

Chen WS, Li JJ, Hong L, Xing ZB, Wang F, Li CQ. Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies. Am J Transl Res. 2016;8:4532–47.PubMedPubMedCentral

Titel: Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer
verfasst von: Zeyu Zhang
Guorong Jia
Guixia Pan
Kai Cao
Qinqin Yang
Hongyu Meng
Jian Yang
Lu Zhang
Tao Wang
Chao Cheng
Changjing Zuo
Publikationsdatum: 04.03.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05729-5

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

P2X7 receptor-specific radioligand 18F-FTTM for atherosclerotic plaque PET imaging

Recent advances in aggregation-induced emission luminogens in photoacoustic imaging

Correction to: Clinical summary of fibroblast activation protein inhibitor‑based radiopharmaceuticals: cancer and beyond

GPC3-targeted immunoPET imaging of hepatocellular carcinomas

Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers